Terms: = Breast cancer AND LIFR, SJS2, 3977, ENSG00000113594, SWS, STWS, CD118 AND Treatment
19 results:
1. Discovery of Novel Fedratinib-Based HDAC/JAK/BRD4 Triple Inhibitors with Remarkable Antitumor Activity against Triple Negative breast cancer.
Zhao C; Zhang Y; Zhang J; Li S; Liu M; Geng Y; Liu F; Chai Q; Meng H; Li M; Li J; Zheng Y; Zhang Y
J Med Chem; 2023 Oct; 66(20):14150-14174. PubMed ID: 37796543
[TBL] [Abstract] [Full Text] [Related]
2. HDAC inhibitors induce lifr expression and promote a dormancy phenotype in breast cancer.
Clements ME; Holtslander L; Edwards C; Todd V; Dooyema SDR; Bullock K; Bergdorf K; Zahnow CA; Connolly RM; Johnson RW
Oncogene; 2021 Aug; 40(34):5314-5326. PubMed ID: 34247191
[TBL] [Abstract] [Full Text] [Related]
3. Beam complexity and monitor unit efficiency comparison in two different volumetric modulated arc therapy delivery systems using automated planning.
Li C; Tao C; Bai T; Li Z; Tong Y; Zhu J; Yin Y; Lu J
BMC Cancer; 2021 Mar; 21(1):261. PubMed ID: 33691654
[TBL] [Abstract] [Full Text] [Related]
4. Discovery of Novel Pyrrolo[2,3-
Liang X; Tang S; Liu X; Liu Y; Xu Q; Wang X; Saidahmatov A; Li C; Wang J; Zhou Y; Zhang Y; Geng M; Huang M; Liu H
J Med Chem; 2022 Jan; 65(2):1243-1264. PubMed ID: 33586434
[TBL] [Abstract] [Full Text] [Related]
5. Prevalence of potential interactions of medications, including herbs and supplements, before, during, and after chemotherapy in patients with breast and prostate cancer.
Lee RT; Kwon N; Wu J; To C; To S; Szmulewitz R; Tchekmedyian R; Holmes HM; Olopade OI; Stadler WM; Von Roenn J
Cancer; 2021 Jun; 127(11):1827-1835. PubMed ID: 33524183
[TBL] [Abstract] [Full Text] [Related]
6. EC359: A First-in-Class Small-Molecule Inhibitor for Targeting Oncogenic lifr Signaling in Triple-Negative breast cancer.
Viswanadhapalli S; Luo Y; Sareddy GR; Santhamma B; Zhou M; Li M; Ma S; Sonavane R; Pratap UP; Altwegg KA; Li X; Chang A; Chávez-Riveros A; Dileep KV; Zhang KYJ; Pan X; Murali R; Bajda M; Raj GV; Brenner AJ; Manthati V; Rao MK; Tekmal RR; Nair HB; Nickisch KJ; Vadlamudi RK
Mol Cancer Ther; 2019 Aug; 18(8):1341-1354. PubMed ID: 31142661
[TBL] [Abstract] [Full Text] [Related]
7. STAT3 activation confers trastuzumab-emtansine (T-DM1) resistance in HER2-positive breast cancer.
Wang L; Wang Q; Gao M; Fu L; Li Y; Quan H; Lou L
Cancer Sci; 2018 Oct; 109(10):3305-3315. PubMed ID: 30076657
[TBL] [Abstract] [Full Text] [Related]
8. Identifying the crosstalk of dysfunctional pathways mediated by lncRNAs in breast cancer subtypes.
Wang L; Li J; Zhao H; Hu J; Ping Y; Li F; Lan Y; Xu C; Xiao Y; Li X
Mol Biosyst; 2016 Mar; 12(3):711-20. PubMed ID: 26725846
[TBL] [Abstract] [Full Text] [Related]
9. Molecular changes in bone marrow, tumor and serum after conductive ablation of murine 4T1 breast carcinoma.
Przybyla BD; Shafirstein G; Vishal SJ; Dennis RA; Griffin RJ
Int J Oncol; 2014 Feb; 44(2):600-8. PubMed ID: 24270800
[TBL] [Abstract] [Full Text] [Related]
10. Salivary flow rates among women diagnosed with benign and malignant tumors.
Napeñas JJ; Miles L; Guajardo-Streckfus C; Streckfus CF
Spec Care Dentist; 2013; 33(3):102-10. PubMed ID: 23600980
[TBL] [Abstract] [Full Text] [Related]
11. YAP-Hippo signalling downstream of leukemia inhibitory factor receptor: implications for breast cancer.
Hergovich A
Breast Cancer Res; 2012 Dec; 14(6):326. PubMed ID: 23216692
[TBL] [Abstract] [Full Text] [Related]
12. lifr is a breast cancer metastasis suppressor upstream of the Hippo-YAP pathway and a prognostic marker.
Chen D; Sun Y; Wei Y; Zhang P; Rezaeian AH; Teruya-Feldstein J; Gupta S; Liang H; Lin HK; Hung MC; Ma L
Nat Med; 2012 Oct; 18(10):1511-7. PubMed ID: 23001183
[TBL] [Abstract] [Full Text] [Related]
13. Pre-treatment imaging and pathology characteristics of invasive breast cancers of limited extent: potential relevance for MRI-guided localized therapy.
Schmitz AC; Pengel KE; Loo CE; van den Bosch MA; Wesseling J; Gertenbach M; Alderliesten T; Mali WP; Rutgers EJ; Bartelink H; Gilhuijs KG
Radiother Oncol; 2012 Jul; 104(1):11-8. PubMed ID: 22652095
[TBL] [Abstract] [Full Text] [Related]
14. Whole genome in vivo RNAi screening identifies the leukemia inhibitory factor receptor as a novel breast tumor suppressor.
Iorns E; Ward TM; Dean S; Jegg A; Thomas D; Murugaesu N; Sims D; Mitsopoulos C; Fenwick K; Kozarewa I; Naceur-Lombarelli C; Zvelebil M; Isacke CM; Lord CJ; Ashworth A; Hnatyszyn HJ; Pegram M; Lippman M
Breast Cancer Res Treat; 2012 Aug; 135(1):79-91. PubMed ID: 22535017
[TBL] [Abstract] [Full Text] [Related]
15. Few changes observed in polysomnographic-assessed sleep before and after completion of chemotherapy.
Roscoe JA; Perlis ML; Pigeon WR; O'Neill KH; Heckler CE; Matteson-Rusby SE; Palesh OG; Shayne M; Huston A
J Psychosom Res; 2011 Dec; 71(6):423-8. PubMed ID: 22118386
[TBL] [Abstract] [Full Text] [Related]
16. breast cancer medications and vision: effects of treatments for early-stage disease.
Eisner A; Luoh SW
Curr Eye Res; 2011 Oct; 36(10):867-85. PubMed ID: 21819259
[TBL] [Abstract] [Full Text] [Related]
17. Embolization of hepatic arterial branches to simplify hepatic blood flow before yttrium 90 radioembolization: a useful technique in the presence of challenging anatomy.
Karunanithy N; Gordon F; Hodolic M; Al-Nahhas A; Wasan HS; Habib N; Tait NP
Cardiovasc Intervent Radiol; 2011 Apr; 34(2):287-94. PubMed ID: 20700593
[TBL] [Abstract] [Full Text] [Related]
18. Adjuvant chemotherapy in breast cancer patients induces temporary salivary gland hypofunction.
Jensen SB; Mouridsen HT; Reibel J; Brünner N; Nauntofte B
Oral Oncol; 2008 Feb; 44(2):162-73. PubMed ID: 17588802
[TBL] [Abstract] [Full Text] [Related]
19. Salivary sIgA concentrations and stimulated whole saliva flow rates among women undergoing chemotherapy for breast cancer: an exploratory study.
Harrison T; Bigler L; Tucci M; Pratt L; Malamud F; Thigpen JT; Streckfus C; Younger H
Spec Care Dentist; 1998; 18(3):109-12. PubMed ID: 9680920
[TBL] [Abstract] [Full Text] [Related]
